Sirius Investors

Adaptimmune Therapeutics plc (ADAP) Financial Metrics

This dashboard provides comprehensive financial metrics and analysis to help evaluate Adaptimmune Therapeutics plc's investment potential. View key valuation ratios, profitability metrics, growth indicators, and historical trends to make informed investment decisions.

Investment Score:
48/100
Fair

Valuation Metrics

P/E Ratio
-1.92
Weak
WeakModerateStrong
P/B Ratio
11.47
Strong
WeakModerateStrong
Earnings Yield
-52.10%
Weak
WeakModerateStrong

Profitability Health

Return on Equity
-597.64%
Weak
WeakModerateStrong
Operating Margin
-38.62%
Weak
WeakModerateStrong
Net Profit Margin
-39.78%
Weak
WeakModerateStrong

Growth Indicators

Revenue Growth
195.34%
Strong
WeakModerateStrong
Net Income Growth
37.81%
Strong
WeakModerateStrong
EPS Growth
50.42%
Strong
WeakModerateStrong

Efficiency & Liquidity

Current Ratio
2.92
Strong
WeakModerateStrong
Quick Ratio
2.80
Strong
WeakModerateStrong
Asset Turnover
0.72x
Moderate
WeakModerateStrong
Inventory Turnover
0.01x
Weak
WeakModerateStrong